Quanterix Stock Soars 12.17% on Merger Hopes

On April 24, 2025, Quanterix's stock surged by 12.17% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Analysts have forecasted that Quanterix will report a loss of $0.98 per share for the current fiscal year. This projection has influenced investor sentiment, contributing to the recent stock price movement.

Quanterix's consensus target price stands at $18.25, suggesting a potential upside of 253.68%. This optimistic outlook is supported by a strong consensus rating, which has bolstered investor confidence in the company's future performance.

Several brokerages have adjusted their target prices for Quanterix. Canaccord Genuity Group, for instance, lowered its target price from $20.00 to $15.00 while maintaining a "buy" rating. This adjustment reflects the dynamic nature of market expectations and the company's evolving prospects.

Quanterix's merger with Akoya Biosciences, Inc. is another significant development that has impacted its stock price. Upon completion of the proposed transaction, Quanterix shareholders will own a portion of the combined entity, which has generated excitement among investors.